London
· Delayed Price · Currency is GBP · Price in CHF Relief Therapeutics Holding Statistics
Total Valuation
Relief Therapeutics Holding has a market cap or net worth of GBP 39.38 million. The enterprise value is 31.95 million.
| Market Cap | 39.38M |
| Enterprise Value | 31.95M |
Important Dates
The next estimated earnings date is Tuesday, April 1, 2025.
| Earnings Date | Apr 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +14.39% |
| Shares Change (QoQ) | +12.10% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 9.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.78 |
| EV / Sales | 4.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.49 |
Financial Position
The company has a current ratio of 3.09, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.09 |
| Quick Ratio | 2.45 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.23 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -64.38% and return on invested capital (ROIC) is -10.23%.
| Return on Equity (ROE) | -64.38% |
| Return on Assets (ROA) | -7.83% |
| Return on Capital (ROIC) | -10.23% |
| Revenue Per Employee | 154,511 |
| Profits Per Employee | -830,942 |
| Employee Count | 49 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 6.56 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +110.25% in the last 52 weeks. The beta is -14.74, so Relief Therapeutics Holding's price volatility has been lower than the market average.
| Beta (5Y) | -14.74 |
| 52-Week Price Change | +110.25% |
| 50-Day Moving Average | 4.52 |
| 200-Day Moving Average | 2.63 |
| Relative Strength Index (RSI) | 37.14 |
| Average Volume (20 Days) | 447 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Relief Therapeutics Holding had revenue of GBP 7.57 million and -40.72 million in losses. Loss per share was -3.26.
| Revenue | 7.57M |
| Gross Profit | 5.19M |
| Operating Income | -10.86M |
| Pretax Income | -45.38M |
| Net Income | -40.72M |
| EBITDA | -8.64M |
| EBIT | -10.86M |
| Loss Per Share | -3.26 |
Balance Sheet
The company has 9.45 million in cash and 2.13 million in debt, giving a net cash position of 7.32 million.
| Cash & Cash Equivalents | 9.45M |
| Total Debt | 2.13M |
| Net Cash | 7.32M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 43.38M |
| Book Value Per Share | 3.46 |
| Working Capital | 8.76M |
Cash Flow
In the last 12 months, operating cash flow was -9.08 million and capital expenditures -67,803, giving a free cash flow of -9.15 million.
| Operating Cash Flow | -9.08M |
| Capital Expenditures | -67,803 |
| Free Cash Flow | -9.15M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 68.56% |
| Operating Margin | -143.38% |
| Pretax Margin | -599.43% |
| Profit Margin | n/a |
| EBITDA Margin | -114.13% |
| EBIT Margin | -143.38% |
| FCF Margin | n/a |
Dividends & Yields
Relief Therapeutics Holding does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.39% |
| Shareholder Yield | -14.39% |
| Earnings Yield | -103.39% |
| FCF Yield | -23.23% |
Stock Splits
The last stock split was on May 5, 2023. It was a reverse split with a ratio of 0.0025.
| Last Split Date | May 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0025 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |